Advertisement
Advertisement
BNTX
BioNTech SE - ADR
102.06
USDSponsored
0.00
0.00%
Apr 28, 15:59 UTC -4
Closed
Pre-Market
101.38
-0.68
-0.67%
BNTX Earnings Reports
Positive Surprise Ratio
BNTX beat 17 of 26 last estimates.
65%
Next Report
Next Week
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$170.33M
/-$2.26
Implied change from Q4 25 (Revenue/ EPS)
-81.23%
/+80.80%
Implied change from Q1 25 (Revenue/ EPS)
-6.82%
/+30.64%
BioNTech SE - ADR earnings per share and revenue
On Mar 10, 2026, BNTX reported earnings of -1.25 USD per share (EPS) for Q4 25, missing the estimate of -0.18 USD, resulting in a -559.28% surprise. Revenue reached 907.40 million, compared to an expected 758.80 million, with a 19.58% difference. The market reacted with a -17.88% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -2.26 USD, with revenue projected to reach 170.33 million USD, implying an increase of 80.80% EPS, and decrease of -81.23% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Apr 29, 2026 For Q1 26
Estimate
$9.06
Actual
$9.47
Surprise
+4.45%
Biogen Inc. Common Stock
Report Date
Apr 29, 2026 For Q1 26
Estimate
$3.07
Actual
$3.57
Surprise
+16.28%
Incyte Genomics Inc
Report Date
Apr 28, 2026 For Q1 26
Estimate
$1.39
Actual
$1.81
Surprise
+29.43%
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Report Date
Apr 28, 2026 For Q1 26
Estimate
$0.20
Actual
$0.27
Surprise
+31.51%
Agios Pharmaceuticals, Inc.
Report Date
Apr 29, 2026 For Q1 26
Estimate
-$1.83
Actual
-$1.69
Surprise
+7.99%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Apr 28, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+60.74%
NeoGenomics, Inc.
Report Date
Apr 28, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+38.89%
Fulcrum Therapeutics, Inc. Common Stock
Report Date
Apr 27, 2026 For Q1 26
Estimate
-$0.30
Actual
-$0.25
Surprise
+17.79%
Nautilus Biotechnolgy, Inc. Common Stock
Report Date
Apr 28, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.12
Surprise
+18.86%
Amarin Corp Plc
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.08
Actual
-$0.09
Surprise
-203.81%
FAQ
What were BioNTech SE - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, BioNTech SE - ADR reported EPS of -$1.25, missing estimates by -559.28%, and revenue of $907.40M, 19.58% above expectations.
How did the market react to BioNTech SE - ADR's Q4 2025 earnings?
The stock price moved down -17.88%, changed from $102.16 before the earnings release to $83.89 the day after.
When is BioNTech SE - ADR expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for BioNTech SE - ADR's next earnings report?
Based on 7
analysts, BioNTech SE - ADR is expected to report EPS of -$2.26 and revenue of $170.33M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement